Emerging biopharmaceutical company SciNeuro Pharmaceuticals has reportedly executed a global license and option agreement with pharma major GlaxoSmithKline (GSK).

The deal focuses on inhibitors of Lp-PLA2, an enzyme involved in the pathogenesis of neurodegenerative disorders. Clinical studies suggest that Lp-PLA2 inhibition activity might enhance cognitive function in patients with Alzheimer's disease.

As per the agreement, SciNeuro will obtain a global license to intellectual property encompassing certain GSK Lp-PLA2 inhibitors. It will be accountable for their development through clinical PoC (proof-of-concept).

After completing PoC studies, GSK has the choice to reclaim rights to the compounds across all territories apart from Greater China, which would be retained by SciNeuro, under pre-decided terms for development and commercialization.

The biopharma company will pay a fee upfront, downstream, and near-term achievements along with royalties to GSK.

If the pharma company uses its option, SciNeuro will get an option exercise fee, royalty payments, and downstream milestones from GSK. Furthermore, GSK will have a right to buy SciNeuro equity.

John Lepore, M.D., SVP and Head of Research at GlaxoSmithKline stated that the agreement allows the company to focus on advancing its internal assets whilst maintaining the option of the pipeline for developing these Lp-PLA2 inhibitors over the years.

Min Li, Ph.D. CEO and Founder of SciNeuro Pharmaceuticals has stated that the Lp-PLA2’s critical role in CNS integrity and the exhibited human pharmacology of its inhibition will enable the company to assess the clinical advantages of these Lp-PLA2 inhibitors in treating CNS diseases.

For the uninitiated, SciNeuro Pharmaceuticals has a robust pipeline of advanced therapeutic candidates to acknowledge neurodegenerative diseases.

The company concentrates on targets that are backed by human biology. It plays a crucial role in controlling foundation biology to attain better chances of success in clinical development.

SciNeuro is dedicated to delivering unique medicines to enhance the lives of patients worldwide.

Source credit:

https://www.prnewswire.com/news-releases/scineuro-pharmaceuticals-announces-a-license-and-option-agreement-with-gsk-to-progress-development-of-novel-therapies-for-cns-diseases-301557923.html